NCT06694558Recruiting
Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 8 Jul 2026
Brief summary (registry, in English)
This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 5 Nov 2024
- Start date
- 1 Mar 2025
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- The Cleveland Clinic
- Diseases
- Chronic kidney disease, Type 1 diabetes
- NCT number
- NCT06694558
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Mar 2025 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- On steroids
- Reported heavy alcohol use or recreational drug use
Other illness
- Diagnosed with cancer, immunosuppression/autoimmune conditions
- Any condition which jeopardizes patient safety or affects monocytes at physician's discretion
Lab values
- Hemoglobin \<9
- On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors use within 30 days
Other
- pregnancy or plans to become pregnant
Who the study is looking for
- T1D CKD subjects:
- Adults, males or females diagnosed with T1D
- Age 18-65 years
- Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2)
- Diagnosed with albuminuria (UACR 30-500 mg/g)
- On insulin injections or pump
- On CGM
- Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0
- Controls: T1D subjects without CKD
- Adults, males or females diagnosed with T1D
- Age 18-65 years
- No CKD (eGFR \>90 ml/min/1.73 m2)
- No albuminuria (UACR \<30 mg/g)
- On insulin injections or pump
- On CGM
- Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cleveland Clinic Coordinator of this site? Confirm its status | Cleveland | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.